Generics and Biosimilars are the Keys to Lower Drug Prices

In September 2021, the Department of Health and Human Service (HHS) released its plan to lower drug prices. Unfortunately, for consumers and patients, the report contained grim statistics that highlighted the cost of drugs in this country and the medical insecurity these prices impose. HHS estimates that each year, “Americans spend more than $1,500 per […]

ACI Joins Coalition Letter in Support of Biosimilar Competition

Today, ACI joined over two dozen groups in sending a letter to Congress in support of legislation that would increase competition for biologic drugs as a means to lower drug prices for patients. On behalf of millions of patients, providers, and taxpayers, we strongly support promoting the use of affordable and safe biosimilars across the […]

Biosimilars: The Grand Experiment

Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance the result may be price controls. This could decrease the incentive to innovate and lead to fewer new drugs being developed. Biologics are among the highest priced […]

THE HILL: Public Quality Standards for Biologic Drugs Promote Transparency and Competition; Don’t Get Rid of Them

A draft of the Lower Health Care Costs Act circulated by the U.S. Senate’s powerful Health, Education, Labor, and Pensions Committee includes a provision that would drastically change how the U.S. develops standards for the strength, quality, and purity of medicines, particularly cutting-edge biologics and biosimilars. Read this op-ed at The Hill to learn why […]

Regulatory Uncertainty and Industry Practices Force Consumers to Overpay on Biologics

Biopharmaceuticals are preparations synthesized from living organisms, especially a human or animal protein, such as a hormone or antitoxin that is used as a diagnostic, preventive, or therapeutic agent. If the preparation is the original drug, it can be patented. Most of us have seen TV adverts for patented new wonder drugs such as Humira, […]

Coalition Sends Letter to FDA: Foster Biosimilar Competition and Reduce Costs

A group of 29 nonprofit organizations filed a letter with the FDA calling on them to foster the development of a robust biosimilars market, which would ultimately reduce prescription drug costs and provide patients with access to more affordable therapies. The letter is available online.

Hill’s Congress Blog: Caution–Drug Competition Not Allowed

About thirty years ago, generic (unbranded) drugs were first approved by the Federal Drug Administration (FDA) for use by patients. These drugs provided competitive alternatives to more expensive name branded pharmaceuticals, and this competition saved consumers $1.68 trillion (not billion) over the last decade, according to the FDA’s Deputy Commissioner. Lower prices from these alternatives […]

Prescription Drug Competition Means Savings

REAL CLEAR POLICY: Competition for some of the priciest drugs may soon be coming to a pharmacy near you. The new development has to do with “biologics,” which are drugs produced in living systems such as plant and animal cells or microorganisms. To Continue Reading, visit Real Clear Policy